Latest
LSI Industries CFO to retire in August 2027 after decade-long tenure
James E. Galeese, CFO since 2017, will step down after over 10 years with the Cincinnati-based lighting and display manufacturer. The company plans to name a successor by mid-2027.
D.E. Shaw discloses $1B+ stake in Sysco amid AI push
Hedge fund D.E. Shaw reveals a more than $1 billion stake in Sysco, as the food distributor accelerates AI-driven efficiency gains and eyes a major acquisition. Sysco’s stock has underperformed over the past year.
AI fintech Tabs raises $92M, valued at $400M amid revenue surge
Tabs, an AI-driven finance automation platform, has grown from a 2023 launch to 180 employees and triple-digit revenue growth, backed by $92M in funding and a $400M valuation.
Michelin shares rise 1.7% after JPMorgan upgrade to Overweight
Stock climbs to €34.68 as JPMorgan lifts price target to €42, citing accelerating truck tire demand and durable growth in high-tech composites.
BOJ’s July 2027 meeting timing fuels speculation on rate hike timing
The Bank of Japan’s next policy meeting, scheduled for July 21-22, 2027, coincides with the expiration of two hawkish board members’ terms, raising questions about the central bank’s normalization strategy.
Euronext wheat hits four-week high as Black Sea disruptions curb exports
Benchmark wheat prices surged 1.8% to €241 per metric ton on Euronext amid escalating war-related shipping disruptions in the Black Sea, redirecting demand to Western Europe.
J&T Express posts 124% profit surge as non-China revenue hits 50%
First-half profit more than doubled to $350.6 million on a 39.5% revenue rise, with half of sales now generated outside China. The express delivery group raised 2026 capex guidance to $800-900 million.
Gold rises as Trump escalates economic pressure on Iran
U.S. sanctions threat against Iran lifts gold, oil prices; Fed rate-hike odds remain low ahead of Jackson Hole. Analysis flags technical resistance and profit-taking risks.
Ultragenyx surges 11% after FDA approval of gene therapy for rare disease
Ultragenyx shares jumped 11.1% in pre-market trading after the FDA granted accelerated approval for GENGLYCOS, the company's first gene therapy. Analysts raised price targets to as high as $58.
Target’s grocery push drives traffic growth, but broader shopper appeal remains key
Food and beverage sales rose 7% in the latest quarter as Target expands private-label offerings, yet grocery still accounts for less than a quarter of total merchandise sales.
U.S. Treasury's Bessent to outline Iran sanctions plan on Monday
Secretary Scott Bessent will detail planned measures against Iran and Treasury bond buybacks at a press conference. Bond yields surged before partially reversing after Wednesday's support announcement.
Robo.ai to release H1 2026 results Sunday after restructuring
The Abu Dhabi-based AI firm will file unaudited financials with the SEC on Sunday, following the disposal of legacy operations and acquisition of Neurovia AI and Quantum Core Capital.
Hays profit rises 3% in FY26 as £50m cost cuts offset fee decline
Pre-exceptional operating profit increased to £48.6m despite an 8% drop in net fees to £905.5m, as restructuring delivered £50m in annualized savings ahead of schedule.
Swiss Prime Site posts 5.1% EPS growth, portfolio value tops CHF 14bn
H1 2026 results show funds from operations per share at CHF 2.15, with full-year guidance raised to the upper end of CHF 4.25-4.30. Asset management AuM rose to CHF 14.8bn.
Swiss Market Index slips 0.26% as Logitech, Swiss Re lead declines
Logitech and Swiss Re shares drop nearly 3% each as SMI falls 0.26%, while Aryzta hits multi-year low after UBS downgrade. Oil near $94, Brent nears $100 as inflation concerns resurface.
Euro Stoxx 50 falls as yields, oil rise; Swiss SMI supported by China trade deal
Eurozone blue-chip index down 0.35% as bond yields climb and crude oil advances; Swiss SMI pares losses to 0.13% on China trade pact. JD Sports drops 14% on weak outlook; Eni, BP gain on higher oil.
Switzerland, China finalize trade deal to eliminate nearly all tariffs on Swiss exports
Updated pact will lift tariffs on 99.8% of Swiss goods to China, including watches, pharmaceuticals and machinery, with annual savings of 244 million francs.
Basilea shares hit eight-year high after strong H1 results
Swiss biopharma firm’s stock surges 3% to CHF 64.30 as first-half revenue beats expectations, driven by Cresemba’s global uptake. Patent cliff looms from late 2027.
Latitude Financial posts 39% H1 2026 profit rise, declares AUD 0.055 dividend
Half-year cash profit surged 39% to AUD 64.3 million as receivables topped AUD 7.3 billion. Interim dividend set at AUD 0.055 per share, fully franked.
Nordic Iron’s Blötberget project NPV rises to $325m on drilling results
Updated mineral resource estimate boosts Blötberget and Väsmanfältet deposits, lifting net present value and extending mine life to 23 years. Pre-feasibility study published as DFS work begins.
Catella Q2 2026 revenue drops 47% as disposal income fades, shares fall 3.7%
Swedish financial services group Catella reported a 47% year-on-year decline in Q2 2026 revenue to SEK 400 million, with underlying net revenue rising 5% to SEK 310 million. Shares slipped 3.7% after the earnings call.
Morgan Stanley lifts semiconductor equipment outlook on stronger DRAM demand
Analysts raise 2026 and 2027 wafer fabrication equipment forecasts as DRAM investment accelerates. Advantest remains top pick after raising guidance.
Ascelia Pharma shares surge 8.2% after FDA setback on Orviglance
Swedish biotech advances despite Complete Response Letter on lead MRI contrast agent; cash runway extended into Q2 2027 after cost cuts.
Nanoform cuts Q2 2026 cash burn to EUR 1.5m as regulatory progress accelerates
Finnish drugmaker trims first-half spending by 33% year-on-year while securing $1m deal and advancing nanoenzalutamide toward market authorization.